Developer docs
API playgroundTry for free, no card

Search company profiles

Karolinska

Full company profile

uuid0009k7k

Namestring
Karolinska
Legal namestring
Karolinska Development AB (publ)
Websiteurl
karolinskadevelopment.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Karolinska Development AB (publ), now operating as KDventures, is a publicly listed Swedish life sciences investment company headquartered in Solna. Founded in 2000, the firm provides retail and institutional investors with diversified exposure to a portfolio of 11 biotech and medtech companies, nine of which are listed on Nasdaq. Its stated proposition is to enable investment in future pharmaceutical and medtech companies "without being a specialist in the field and without putting all eggs in the same basket," addressing the information asymmetry that prevents non-specialist investors from accessing early-stage life science opportunities directly.

The company operates as a minority-holding investment vehicle, maintaining equity stakes and active board involvement in portfolio companies spanning therapeutic areas including chronic hepatitis B and D (SVF Vaccines), chronic kidney disease with anemia (Modus Therapeutics), osteogenesis imperfecta (BOOST Pharma), neuropathic pain (PharmNovo), cardiac conditions (AnaCardio), and neurological disorders (Umecrine Cognition). Karolinska Development holds a 33% stake in SVF Vaccines, which is pursuing a reverse acquisition of Novakand Pharma for a Nasdaq First North listing. The firm does not develop products itself; portfolio companies commercialize their own therapeutic candidates and medical technologies through standard pharmaceutical and medtech distribution channels.

KDventures generates economics primarily through changes in portfolio fair value and realized exit proceeds rather than recurring operating revenue, funded in part by equity issuances to public shareholders. Recent capital actions include a SEK 7.5 million follow-on into BOOST Pharma (October 2025), a SEK 202.6 million rights issue of series B shares (January 2026), and a SEK 23.9 million directed share issue (June 2026). The company is led by CEO Viktor Drvota and Chairman Ben Toogood, with a core team of 1-10 employees. No revenue figure is disclosed in available materials.

Short descriptiontext

Karolinska Development (now KDventures) is a publicly listed Swedish life sciences investment company that holds minority stakes in 11 biotech and medtech portfolio companies, providing retail and institutional investors diversified exposure to early-stage pharmaceutical and medical technology assets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life science investments, biotech venture capital, medtech investment, pharmaceutical portfolio investing, healthcare innovation funding
Product category
Life Sciences Investment
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Operations, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Karolinska Development AB (operating as KDventures) is a Swedish life sciences investment company that provides retail and institutional investors with access to a diversified portfolio of early-stage and listed pharmaceutical and medtech companies. The firm invests in, and provides strategic and financial support to, portfolio companies developing therapeutic candidates and medical technologies, enabling investors to gain exposure to life science innovation without requiring specialist expertise.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

KDventures operates as a life sciences investment company offering a single unified investment platform that provides exposure to a portfolio of 11 life science companies across 9 Nasdaq listings. The company's investment approach focuses on early-stage to established pharmaceutical and medtech companies, with the portfolio including portfolio companies such as Modus Therapeutics (sevuparin for chronic kidney disease with anemia), BOOST Pharma (BT-101 stem cell therapy for osteogenesis imperfecta), SVF Vaccines (SVF-001 immunotherapy for hepatitis B and D), PharmNovo (PN6047 for neuropathic pain), AnaCardio, and Umecrine Cognition (golexanolone). The company also facilitates investment through mechanisms such as rights issues and directed share issuances.

Product and service1 record
1KDventures Investment Platform
CategoryInvestment Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Cirio Advokatbyrå AB
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Serving as legal adviser for the rights issue transaction.

2Nordic Issuing AB
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Serving as issuing agent for the rights issue transaction.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
1Kurma Partners
TypeEmerging player
Description

European venture capital firm focused on early- to mid-stage biotech and medtech. Adjacent to KDventures' investment focus, though private and venture-led rather than publicly listed.

2Polar Capital Global Healthcare Trust
TypeDirect peer
Description

UK-listed trust investing in global healthcare equities. Comparable as a publicly traded diversified healthcare/biotech investor with similar end-investor proposition.

3BB Biotech AG
TypeDirect peer
Description

Swiss-listed closed-end fund that invests in a concentrated portfolio of public and private biotech companies. Directly comparable to KDventures as a publicly traded vehicle providing diversified biotech exposure.

4Arix Bioscience plc
TypeDirect peer
Description

London-listed life sciences investment company backing early and growth-stage therapeutic companies. Directly comparable as a publicly traded biotech investment vehicle similar to KDventures.

5Worldwide Healthcare Trust plc
TypeDirect peer
Description

UK-listed investment trust focused on global healthcare equities including biotech and medtech. Comparable in providing listed-vehicle exposure to a diversified life sciences portfolio.

6International Biotechnology Trust plc
TypeDirect peer
Description

UK-listed investment trust providing diversified exposure to global biotech equities. Comparable to KDventures as a long-standing publicly listed biotech investor offering portfolio diversification.

7Syncona Limited
TypeDirect peer
Description

UK-listed life sciences investment trust that builds, holds and supports early-stage biotech companies. Comparable in providing public investors access to a portfolio of clinical-stage therapeutics companies.

8HBM Healthcare Investments AG
TypeDirect peer
Description

Swiss-listed investor focused on private and small-cap public healthcare companies across therapeutics, medtech and diagnostics. Closely mirrors KDventures' model of holding minority stakes across a diversified life sciences portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment32 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Karolinska

Life Sciences Investmentkarolinskadevelopment.com

Karolinska Development (now KDventures) is a publicly listed Swedish life sciences investment company that holds minority stakes in 11 biotech and medtech portfolio companies, providing retail and institutional investors diversified exposure to early-stage pharmaceutical and medical technology assets.

What Karolinska does

Karolinska Development AB (publ), now operating as KDventures, is a publicly listed Swedish life sciences investment company headquartered in Solna. Founded in 2000, the firm provides retail and institutional investors with diversified exposure to a portfolio of 11 biotech and medtech companies, nine of which are listed on Nasdaq. Its stated proposition is to enable investment in future pharmaceutical and medtech companies "without being a specialist in the field and without putting all eggs in the same basket," addressing the information asymmetry that prevents non-specialist investors from accessing early-stage life science opportunities directly.

The company operates as a minority-holding investment vehicle, maintaining equity stakes and active board involvement in portfolio companies spanning therapeutic areas including chronic hepatitis B and D (SVF Vaccines), chronic kidney disease with anemia (Modus Therapeutics), osteogenesis imperfecta (BOOST Pharma), neuropathic pain (PharmNovo), cardiac conditions (AnaCardio), and neurological disorders (Umecrine Cognition). Karolinska Development holds a 33% stake in SVF Vaccines, which is pursuing a reverse acquisition of Novakand Pharma for a Nasdaq First North listing. The firm does not develop products itself; portfolio companies commercialize their own therapeutic candidates and medical technologies through standard pharmaceutical and medtech distribution channels.

KDventures generates economics primarily through changes in portfolio fair value and realized exit proceeds rather than recurring operating revenue, funded in part by equity issuances to public shareholders. Recent capital actions include a SEK 7.5 million follow-on into BOOST Pharma (October 2025), a SEK 202.6 million rights issue of series B shares (January 2026), and a SEK 23.9 million directed share issue (June 2026). The company is led by CEO Viktor Drvota and Chairman Ben Toogood, with a core team of 1-10 employees. No revenue figure is disclosed in available materials.

Karolinska firmographics

Firmographics
Name
Karolinska
Legal name
Karolinska Development AB (publ)
Website
https://karolinskadevelopment.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
1–10 employees
Short description
Karolinska Development (now KDventures) is a publicly listed Swedish life sciences investment company that holds minority stakes in 11 biotech and medtech portfolio companies, providing retail and institutional investors diversified exposure to early-stage pharmaceutical and medical technology assets.
Ownership category
akta.pro rank

Where Karolinska is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Karolinska business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Others

Marketing channels2 records

Karolinska product offering

Product offering

Core offering

Karolinska Development AB (operating as KDventures) is a Swedish life sciences investment company that provides retail and institutional investors with access to a diversified portfolio of early-stage and listed pharmaceutical and medtech companies. The firm invests in, and provides strategic and financial support to, portfolio companies developing therapeutic candidates and medical technologies, enabling investors to gain exposure to life science innovation without requiring specialist expertise.

Product overview

KDventures operates as a life sciences investment company offering a single unified investment platform that provides exposure to a portfolio of 11 life science companies across 9 Nasdaq listings. The company's investment approach focuses on early-stage to established pharmaceutical and medtech companies, with the portfolio including portfolio companies such as Modus Therapeutics (sevuparin for chronic kidney disease with anemia), BOOST Pharma (BT-101 stem cell therapy for osteogenesis imperfecta), SVF Vaccines (SVF-001 immunotherapy for hepatitis B and D), PharmNovo (PN6047 for neuropathic pain), AnaCardio, and Umecrine Cognition (golexanolone). The company also facilitates investment through mechanisms such as rights issues and directed share issuances.

Differentiator

Problem solved

Functional benefit

Products and services

  • KDventures Investment Platform

Companies that use Karolinska

Customer profile

Segments1 record

Ideal customer profiles2 records

Karolinska technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Karolinska partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Cirio Advokatbyrå ABminorImplementation/ SI/ Consulting PartnerServing as legal adviser for the rights issue transaction.
  • Nordic Issuing ABminorImplementation/ SI/ Consulting PartnerServing as issuing agent for the rights issue transaction.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Karolinska competitors and assessment

Company assessment

Emerging players

  • Kurma Partners: European venture capital firm focused on early- to mid-stage biotech and medtech. Adjacent to KDventures' investment focus, though private and venture-led rather than publicly listed.

Direct peers

  • Polar Capital Global Healthcare Trust: UK-listed trust investing in global healthcare equities. Comparable as a publicly traded diversified healthcare/biotech investor with similar end-investor proposition.
  • BB Biotech AG: Swiss-listed closed-end fund that invests in a concentrated portfolio of public and private biotech companies. Directly comparable to KDventures as a publicly traded vehicle providing diversified biotech exposure.
  • Arix Bioscience plc: London-listed life sciences investment company backing early and growth-stage therapeutic companies. Directly comparable as a publicly traded biotech investment vehicle similar to KDventures.
  • Worldwide Healthcare Trust plc: UK-listed investment trust focused on global healthcare equities including biotech and medtech. Comparable in providing listed-vehicle exposure to a diversified life sciences portfolio.
  • International Biotechnology Trust plc: UK-listed investment trust providing diversified exposure to global biotech equities. Comparable to KDventures as a long-standing publicly listed biotech investor offering portfolio diversification.
  • Syncona Limited: UK-listed life sciences investment trust that builds, holds and supports early-stage biotech companies. Comparable in providing public investors access to a portfolio of clinical-stage therapeutics companies.
  • HBM Healthcare Investments AG: Swiss-listed investor focused on private and small-cap public healthcare companies across therapeutics, medtech and diagnostics. Closely mirrors KDventures' model of holding minority stakes across a diversified life sciences portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Karolinska social profiles

Digital presence

Karolinska financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Karolinska leadership team

Management profile

Number of profiles

Profiles2 records

Karolinska subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Karolinska funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Karolinska M&A and investment

M&A and investment

M&A

Investments32 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karolinska

What does Karolinska do?

Karolinska Development AB (operating as KDventures) is a Swedish life sciences investment company that provides retail and institutional investors with access to a diversified portfolio of early-stage and listed pharmaceutical and medtech companies. The firm invests in, and provides strategic and financial support to, portfolio companies developing therapeutic candidates and medical technologies, enabling investors to gain exposure to life science innovation without requiring specialist expertise.

Is Karolinska a public or private company?

Karolinska is a public company. It is classified as public and is currently operating.

When was Karolinska founded?

Karolinska was founded in 2000. It employs 1 to 10 people.

Where is Karolinska based?

Karolinska is headquartered in Solna, Sweden, in the Europe region.

Who are Karolinska's main competitors?

Kurma Partners is listed as an emerging player. Direct peers are Polar Capital Global Healthcare Trust, BB Biotech AG, Arix Bioscience plc, Worldwide Healthcare Trust plc, International Biotechnology Trust plc, Syncona Limited and HBM Healthcare Investments AG.

Does Karolinska have an API?

No public API is recorded for Karolinska.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireKarolinska Development’s portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreementSVF Vaccines and Novakand Pharma entered a reverse acquisition agreement, with Novakand acquiring all SVF shares in exchange for newly issued shares valued at about SEK 55 million. SVF shareholders will receive 66.7% of the combined company, and the deal is expected to be completed in Q1 2026. The combined company will focus on vaccine development, including a planned Phase 1 study for SVF-001.GlobeNewswireKarolinska Development AB (publ) announces the outcome of the rights issue and change of the company name to KDventures ABKarolinska Development AB announced the outcome of its Series B rights issue, which was subscribed to about 57% (23% with rights, 2% without). The company will receive approximately SEK 115.2 million, and its name will change to KDventures AB, with a new ticker KDV. The allotment is subject to ISP approval.GlobeNewswireKarolinska Development’s portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparinDilafor signed a binding term sheet with Exeltis for an exclusive semi-global license to tafoxiparin for priming of labor, excluding China and Japan. Exeltis will fund pivotal trials and commercialization, with milestone payments and royalties. The deal could shift labor induction from hospital to home use.GlobeNewswireKarolinska Development AB (publ) announces publication of information document in connection with upcoming rights issueKarolinska Development AB has published an information document in connection with a rights issue of series B shares valued at approximately SEK 202.6 million, which was approved by an extraordinary general meeting on 8 January 2026. The subscription period is set to run from 13 January to approximately 12 February 2026, with trading in subscription rights occurring from 13 to 27 January 2026. Redeye AB is serving as financial adviser, Cirio Advokatbyrå AB as legal adviser, and Nordic Issuing AB as issuing agent for the transaction.GlobeNewswireKarolinska Development’s Extraordinary General Meeting 2026Karolinska Development's shareholders approved a rights issue of up to 675,193,985 series B shares at SEK 0.30 each, and amended the company name to KDventures AB. The share capital limits were set between SEK 2.65 million and 10.6 million, with share counts between 265 million and 1.06 billion.GlobeNewswireKarolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine developmentSVF Vaccines signed a non-binding letter of intent with Novakand Pharma for a reverse takeover, aiming to list on Nasdaq First North Premier. The deal would give SVF Vaccines shareholders about 67% of Novakand, and the company plans to raise capital for its SVF-001 hepatitis B and D vaccine program. A Phase 1 study is expected 24 months after closing.GlobeNewswireKarolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine developmentKarolinska Development's portfolio company SVF Vaccines has signed a non-binding letter of intent with Novakand Pharma AB for a reverse takeover that would result in SVF Vaccines listing on Nasdaq First North Premier, with SVF Vaccines shareholders expected to hold approximately 67% of the combined entity. The transaction includes a financing plan to accelerate development of SVF-001, the company's lead vaccine program targeting hepatitis B and D, with a Phase 1 clinical study expected to complete approximately 24 months from closing. Karolinska Development, which currently holds a 33% stake in SVF Vaccines, views this reverse listing as an optimal path to fund the vaccine development and gain exposure to a broader investor base.GlobeNewswireKarolinska Development’s portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and DSVF Vaccines presented preclinical data on its immunotherapy candidate SVF-001 at the HepDart scientific meeting in Honolulu, Hawaii (December 7-11), demonstrating sustained antiviral activity against hepatitis D virus up to six weeks after treatment in preclinical models. The follow-up data showed durable reductions in hepatitis D virus RNA through the six-week follow-up period, supporting the company's goal of achieving long-lasting immunological control in patients with chronic hepatitis B and D coinfections. Karolinska Development, which holds a 33 percent stake in SVF Vaccines, announced the results, with CEO Viktor Drvota calling the findings promising for a potential cure.YahooKarolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemiaKarolinska Development's portfolio company Modus Therapeutics has dosed the first patient in the phase 2a clinical study of sevuparin for treating chronic kidney disease with anemia. The study, conducted in Italy with 50-60 patients, will evaluate repeated dosing safety and clinically relevant efficacy outcomes including effects on hemoglobin and hepcidin levels. This milestone follows regulatory approval and aligns with the company's previously communicated development schedule, marking continued progress in the clinical program.GlobeNewswireKarolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01Karolinska Development's portfolio company AnaCardio has reported positive top-line results from its Phase 2a clinical trial GOAL-HF1 evaluating drug candidate AC01 in patients with heart failure with reduced ejection fraction, with the study meeting its primary safety and tolerability endpoint. The trial enrolled 26 patients across 13 European heart failure centers and showed encouraging efficacy signals, with the company planning to initiate a Phase 2b study in mid-2026.